---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-026601"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T14:55:53.789187+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.0
calibrated_materiality_score: 0.0
confidence: "low"
source: SEC EDGAR
---

# ADMA Biologics posts May 2024 corporate presentation; no material updates disclosed

## Summary
- Corporate presentation titled 'Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology' made available.
- Presentation intended for use in discussions with potential investors, strategic partners, and analysts.
- No new financial guidance, product milestones, or material operational changes were included in the filing.

## SEC filing metadata
- accession: 0001140361-24-026601
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.0
- calibrated_materiality_score: 0.0
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124026601/0001140361-24-026601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124026601/ef20029374_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-026601
- JSON: https://secwatch.observer/filing/0001140361-24-026601.json
- Plain text: https://secwatch.observer/filing/0001140361-24-026601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.